CHENGDU, China, Nov. 8, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a pharmaceutical company that develops, manufactures and sells patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, today announced that the senior management will host the earnings conference call for the first quarter of fiscal year 2011 ending September 30, 2010 at 9:00 a.m. ET on Thursday, November 11, 2010.
Interested parties may access the call by dialing +1-877-941-4774 (U.S.), or +1-480-629-9764 (International). The conference ID is 4384159. It is advisable to dial in approximately 5 minutes prior to the start of the call.
A replay will be available from 12 noon ET on November 11, 2010 till November 25, 2010 by dialing 1-877-870-5176 (U.S.) or 1-858-384-5517 (International), Replay Pin Number: 4384159.
This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://viavid.net/dce.aspx?sid=00007DBB
About Tianyin Pharmaceutical
Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. Tianyin has a pipeline of 10 products pending SFDA approval targeting cardiovascular conditions, women's health, immune system and respiratory disorders. Tianyin has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact:Investors Contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc.Web: http://www.tianyinpharma.comEmail: Dr.Tong@tianyinpharma.comTel: +86-28-8551-6696 (Chengdu, China)+1-949-350-6999 (U.S.)Address:23rd Floor Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2010 PR Newswire.
All rights reserved